Gyre Therapeutics (GYRE) EBIT Margin (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly EBIT Margin of 41.54% for Q1 2026, down 5185.0% year-over-year from 0.82% in Q1 2025, and down 13194.75% quarter-over-quarter from 0.32% in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) EBIT Margin (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported EBIT Margin for 16 consecutive years, with 41.54% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT Margin fell 5185.0% year-over-year to 41.54%; the TTM figure through Mar 2026 stood at 0.12% (down 1042.0% YoY), while the FY2025 annual figure was 9.85%, down 543.0% from the prior year.
- EBIT Margin fell to 41.54% in Q1 2026 per GYRE's latest filing, from 0.32% in the prior quarter.
- Across five years, EBIT Margin topped out at 39.84% in Q3 2023 and bottomed at 1851.51% in Q1 2022.
- Historically, EBIT Margin has averaged 137.76% across 5 years, with a median of 10.3% in 2025.
- Annual changes were most pronounced in 2022 — EBIT Margin sank 32200 bps — and 2023, when it soared 187824 bps.
- Gyre Therapeutics' EBIT Margin stood at 22.13% in 2022, then slumped by 1425 bps to 337.53% in 2023, then jumped by 101 bps to 2.39% in 2024, then plunged by 87 bps to 0.32% in 2025, then sank by 13195 bps to 41.54% in 2026.
- Business Quant data shows GYRE's EBIT Margin at 41.54% in Q1 2026, 0.32% in Q4 2025, and 22.66% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | -49.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -49.35% |
| Mar 31, 2026 | -41.54% |
| Dec 31, 2025 | 0.32% |
| Sep 30, 2025 | 22.66% |
| Jun 30, 2025 | -7.53% |
| Mar 31, 2025 | 10.30% |
| Dec 31, 2024 | 2.39% |
| Sep 30, 2024 | 16.61% |
| Jun 30, 2024 | 12.66% |
| Mar 31, 2024 | 29.70% |
| Dec 31, 2023 | -337.53% |
| Sep 30, 2023 | 39.84% |
| Jun 30, 2023 | 16.96% |
| Mar 31, 2023 | 26.73% |
| Dec 31, 2022 | -22.13% |
| Mar 31, 2022 | -1,851.51% |
| Dec 31, 2021 | -832.50% |
| Sep 30, 2021 | -1,097.39% |
| Jun 30, 2021 | -1,759.19% |
| Mar 31, 2021 | -1,529.52% |